TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04646941

Intervention type: OTHER
Intervention: regular treatment
Description: The patients with or without OSA received regular hypoglycemic drugs.

Intervention type: OTHER
Intervention: regular treatment
Description: The patients with or without OSA received regular hypoglycemic drugs.
Study: NCT02102516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPRIX(intranasal ketorolac tromethamine)
Description: Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing \>=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug.
Study: NCT02939833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp Nerve Blocks With Ropivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scalp Nerve Blocks With Saline
Study: NCT02603393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone
Description: Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
Study: NCT01136876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol-320
Description: Iodixanol-320 single administration for percutaneous coronary intervention procedure
Study: NCT03396900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhBMP-2 Protein, Recombinant
Description: Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Corticotomy
Description: A conventional PAOO Surgical procedure will be performed for individuals in this arm
Study: NCT00854191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simulator training
Description: 4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: simulator training
Description: 4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
Study: NCT00533546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Protein C
Description: Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
Study: NCT03576742

Intervention type: DIAGNOSTIC_TEST
Intervention: potential biomarkers
Description: facs analysis, microbiome analysis
Study: NCT02755415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIWIN Robotic Gait Training System
Description: HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Standing Table
Description: As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
Study: NCT02219568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT enterography
Description: CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video capsule endoscopy
Description: Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
Study: NCT02879760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-MAGEA3
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1-MAGEA3
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT03569072

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functionally adapted, dose escalated VMAT radiotherapy
Description: Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
Study: NCT04277936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
Study: NCT01175590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of Besivance administered to affected eye for 7 days
Study: NCT00634465

Intervention type: DEVICE
Intervention: RSA Beads
Description: Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
Study: NCT04251624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Therapy
Description: A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Education
Description: A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
Study: NCT01674985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
Study: NCT01489761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: drug eluting stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: drug eluting stent implantation
Study: NCT02072694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75 grams of glucose plus water solution
Description: A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 75 grams of glucose plus water solution
Description: A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study: NCT00755963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: maltodextrin
Study: NCT01343836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Tenocyte Implantation
Description: Intratendinous ATI (autologous tenocyte injection) with eccentric exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intratendinous saline injection with eccentric exercises
Study: NCT00617617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prevastein HC®
Description: Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group - Control Group participants will receive an identical placebo.
Study: NCT01469091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking intervention.
Description: Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
Study: NCT00432211

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avotermin
Description: Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration.
Study: NCT00987753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-377202
Description: For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
Study: NCT00719849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 30mg/Kg Days -6 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg/Kg Day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg/Kg Day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40mg/m2 Days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40mg/m2 Days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Single or double unit umbilical cord blood transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Single or double unit umbilical cord blood transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: 200 cGy Day -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: 200 cGy Day -1
Study: NCT03806374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: cisatracurium
Study: NCT03806374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: cisatracurium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine
Study: NCT00763438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Flexible dose
Study: NCT02190474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Group
Description: Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
Study: NCT00599521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene lotion 0.1%
Description: Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene Lotion Vehicle
Description: Vehicle will be applied topically to the face, once a day, for 12 weeks
Study: NCT01080443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil Capsule 250 mg
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil Capsule 250 mg
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT02841813

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03512860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E4/DRSP
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E4/DRSP
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL
Description: Administered as specified in the treatment arm.
Study: NCT03889067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi challenge
Description: The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
Study: NCT02585934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101
Description: once daily, oral, 35 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, pill manufactured to match RVT-101 35 mg tablet
Study: NCT03686449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cultured Autologous Keratinocyte Suspension
Description: New method for treatment of post-burn raw area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Stem cell-Keratinocyte Suspension
Description: New method for treatment of post-burn raw area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft
Description: Traditional method for treatment of post-burn raw area
Study: NCT00005727

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Classroom-based nutrition education curriculum designed for individuals with low literacy skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
Study: NCT00746018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Description: The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
Study: NCT02149329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of imipenem-cilastatin or meropenem
Description: Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
Study: NCT03967496

Intervention type: PROCEDURE
Intervention: Types of Anesthesia
Description: General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively.

Intervention type: PROCEDURE
Intervention: Types of Anesthesia
Description: General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively.

Intervention type: PROCEDURE
Intervention: Types of Anesthesia
Description: General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively.

Intervention type: PROCEDURE
Intervention: Access of Surgery
Description: Type of surgical access

Intervention type: PROCEDURE
Intervention: Access of Surgery
Description: Type of surgical access

Intervention type: PROCEDURE
Intervention: Access of Surgery
Description: Type of surgical access

Intervention type: OTHER
Intervention: Comorbidities
Description: A patient may have more than one comorbidity

Intervention type: OTHER
Intervention: Comorbidities
Description: A patient may have more than one comorbidity

Intervention type: OTHER
Intervention: Comorbidities
Description: A patient may have more than one comorbidity

Intervention type: DRUG
Intervention: Preoperative Medication
Description: Preoperative medications

Intervention type: DRUG
Intervention: Preoperative Medication
Description: Preoperative medications

Intervention type: DRUG
Intervention: Preoperative Medication
Description: Preoperative medications

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood test
Description: Preoperative and Intraoperative Investigations

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood test
Description: Preoperative and Intraoperative Investigations

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood test
Description: Preoperative and Intraoperative Investigations
Study: NCT03151408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: 60 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: SC or IV injection